Prime Medicine (PRME) Q3 2026 earnings review
Prime Medicine starts human liver trials and refills its cash
Prime Medicine, a biotechnology developer of one-time gene editing treatments, moved its liver programs into human testing while raising cash to stay afloat. Chief executive Allan Reine announced the first patient dosing in its Wilson disease trial and regulatory clearance to begin human trials in Alpha-1 Antitrypsin Deficiency. Operating expenses fell 20% from a year ago, and a November stock sale brought in $135 million net to extend the cash outlook through 2027.
| Total operating expenses | $44.1M -20% from a year ago |
|---|---|
| Pro-forma cash after November offering | $209.5M $74.8M at Q3 end before offering |
| Quarterly cash burn (by our math) | $34.0M $40.4M last quarter |
| Cash runway outlook | Extended through 2027 (previously into 2027) |
⚖️ Verdict: 🟢 Bullish
The story got better because the company crossed into human liver testing and removed its immediate funding crunch. Dosing patients in Wilson disease and clearing the second liver drug for trials puts two wholly owned programs on track for initial human data in 2027. One caution: September cash had dropped to $75 million before the November stock sale, and by our math the new money caps average quarterly cash use at $42 million through 2027.
The question now is whether the universal liver delivery system safely edits enough cells in humans before the new cash runs low in late 2027. If the 2027 data show clear gene correction in both diseases, the shared platform works across multiple drugs; if editing falls short, the company will face another fundraise from a weaker position. Initial clinical results in 2027 will decide it.
🐂 Bull Case
First Patient Dosed in Liver Editing Trial
Prime Medicine develops one-time gene editing treatments designed to repair faulty DNA. Chief executive Allan Reine said the company is now testing its technology inside the human body, starting with liver diseases. In October, doctors dosed the first patient in a Phase 1/2 trial of PM577a, an experimental treatment for Wilson disease, a genetic disorder where copper builds up in the body.
This trial matters because Prime Medicine previously proved its editing worked only in cells removed from a patient and edited in a lab. Testing PM577a directly inside patients is the first real test of its lipid nanoparticle (LNP) delivery system, a microscopic fat bubble that carries the gene editor to the liver. The Food and Drug Administration (FDA) also granted Rare Pediatric Disease status to the program.
What to watch: initial clinical data from the PM577a Wilson disease trial in 2027. Safe copper reduction in patients would show the company can edit genes directly inside the human liver.
Second Liver Drug Cleared for Human Trials
In September, the FDA cleared Prime Medicine's Investigational New Drug (IND) application — regulatory permission to start human trials — for PM647 in Alpha-1 Antitrypsin Deficiency (AATD), an inherited disorder that damages the lungs and liver. "In just months, our two wholly owned liver programs have moved into, or been cleared for, clinical development," Reine said.
The clearance follows a July arbitration win against rival Beam Therapeutics that confirmed Prime Medicine's rights to the drug. Because PM647 uses the same liver delivery system as the Wilson disease drug, it lowers development cost and addresses about 100,000 US patients carrying the target mutation.
What to watch: the start of patient dosing in the PM647 trial and initial clinical data in 2027. Positive safety and protein-restoration readings in the initial lung cohort would let the study expand into liver-disease patients.
Operating Spending Dropped Twenty Percent From Last Year
Prime Medicine cut its total operating expenses by 20.0% from a year ago to $44.1 million, narrowing its quarterly net loss from $50.6 million to $39.0 million. Last year's staff cuts, lower lab equipment repair costs, and the completion of the Beam legal arbitration drove the savings.
- Research and development (R&D) spending: $34.1 million, down 22.4% from $44.0 million a year ago
- General and administrative (G&A) spending: $10.0 million, down 10.6% from $11.2 million a year ago
- Quarterly cash reduction: $34.0 million in Q3, down from $40.4 million in Q2 and $42.2 million in Q1 by our math
Lower overhead and lab repair bills matter because the biotech company is simultaneously starting two global human trials. Keeping quarterly cash use near $34 million gives management more time to produce human data before needing additional funds.
What to watch: R&D expenses in the fourth quarter as PM647 trial sites open. A sharp cost rise would shorten the company's newly extended cash runway.
🐻 Bear Case
Cash Dropped Low Before Dilutive Share Sale
Reine said the November stock offering "strengthens our balance sheet and provides additional resources needed to advance these programs through key clinical milestones." Before that sale closed, Prime Medicine ended September with $74.8 million in total cash (including restricted cash) and $8.4 million in stockholders' equity, down from $191.4 million in cash at year-end.
At the third quarter's $34.0 million burn rate, the September balance covered barely two quarters of work, forcing management to sell stock in November for $143.7 million gross ($134.7 million net after $9.0 million in fees). Weighted-average shares had already risen 10.8% from a year ago to 177.9 million before the new shares.
Even with $209.5 million in combined cash after the offering, management's outlook says the money lasts only through 2027. Because initial data from both liver trials arrive in 2027, the company will likely need to raise money again right as those results come out.
What to watch: the exact share count in the third-quarter 10-Q filing or fourth-quarter release. The number of shares issued in November will show how much ownership existing holders gave up to fund 2027 operations.
Lead Drug Filing Still Awaits FDA Alignment
Prime Medicine plans to submit a Biologics License Application (BLA) — a request for FDA permission to sell a biologic drug — in the first half of 2027 for PM359, its treatment for Chronic Granulomatous Disease (CGD), an inherited immune deficiency. The company said it continues to "engage with the FDA on the most efficient path to approval."
Management deprioritized internal spending on CGD in 2025 after treating the first two patients, shifting resources to its liver programs. Because the first half of 2027 is less than two quarters away, ongoing discussions mean the company has not yet locked in final regulatory agreement on whether the small dataset suffices for filing.
What to watch: announcement of final FDA alignment on the PM359 filing package before mid-2027. A request for additional clinical data would delay the company's first commercial application and potential rare pediatric priority review voucher.
👓 Other Themes
FDA Draft Rules Could Aid Follow-On Programs
Reine noted that recent FDA draft rules on individualized genome editing could "create a meaningful opportunity for us to extend Prime Editing therapies to additional diseases." Meanwhile, the company is doing early lab work on PM577b, a follow-on Wilson disease drug targeting the R778L mutation common in East Asia using the same liver delivery system.
💲 Other KPIs
Collaboration revenue from related parties — payments recognized from its immune and cancer cell-therapy partnership with Bristol Myers Squibb — more than tripled to $4.2 million from $1.2 million a year ago and $1.2 million last quarter. While still small next to $44.1 million in expenses, higher partnership revenue slightly reduces net cash burn.
Total liabilities — obligations including deferred collaboration revenue and lease commitments — edged down to $205.4 million from $209.2 million in June and $221.9 million at the end of 2025. Because cash dropped before the November stock sale, liabilities reached 96.1% of total assets on September 30 by our math.
🔮 Guidance
Raised. Prime Medicine now expects its $209.5 million in combined cash (September cash plus $134.7 million net from the November share sale) to fund operations through the end of 2027, up from its prior plan of into 2027. By our math, funding the five quarters from October 2026 through December 2027 caps average quarterly cash burn at $41.9 million, compared with $34.0 million in Q3.
Unchanged. The biotech group still plans to report initial human data in 2027 from both its PM577a trial in Wilson disease and its PM647 trial in Alpha-1 Antitrypsin Deficiency. Management has held this 2027 target steady for four straight quarters while moving both programs through regulatory clearance.
Unchanged. Management continues to plan an approval submission for PM359 in Chronic Granulomatous Disease during the first half of 2027. The timeline matches the schedule first set last quarter, contingent on ongoing FDA discussions.
❓ Key Questions
How many shares did Prime Medicine issue in November?
The release gave gross proceeds of $143.7 million and net proceeds of $134.7 million from the November offering, but omitted the offering price and exact number of shares sold. Investors need the new share count to calculate total dilution.
What still needs settling with the FDA on PM359?
With the first half of 2027 less than two quarters away, Prime Medicine is still discussing the approval path for PM359 with regulators. Management has not said whether the agency agreed that existing clinical data are sufficient without treating more patients.
When will Cystic Fibrosis preclinical proof-of-concept data arrive?
At the end of 2025, management pointed to anticipated preclinical proof-of-concept data in 2026 for its Cystic Fibrosis program funded by the Cystic Fibrosis Foundation. This release gave no timeline for that data as 2026 nears its close.